Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 20/20 | 0.68 |
| ▸ | HCRTR1 | O43613 | 18/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | HTR2A | P28223 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486920 | 0.90 | HCRTR2 (0.83) | HCRTR2HCRTR1CYP3A4HTR2A | |
| SCHEMBL3487239 | 0.86 | HCRTR2 (0.75) | HCRTR2HCRTR1CYP3A4HTR2A | |
| SCHEMBL2279413 | 0.85 | HCRTR2 (0.64) | HCRTR2HCRTR1CYP3A4HTR2A | |
| SCHEMBL3486925 | 0.83 | HCRTR2 (0.69) | HCRTR2HCRTR1CYP3A4HTR2A | |
| SCHEMBL2276855 | 0.83 | HCRTR2 (0.66) | HCRTR2HCRTR1CYP3A4HTR2A | |
| SCHEMBL3485313 | 0.83 | HCRTR2 (0.68) | HCRTR2HCRTR1CYP3A4HTR2A | |
| SCHEMBL15894168 | 0.82 | HCRTR2 (0.85) | HCRTR2HCRTR1CYP3A4HTR2A | |
| SCHEMBL13498691 | 0.82 | HCRTR2 (0.70) | HCRTR2HCRTR1CYP3A4HTR2A | |
| SCHEMBL3485979 | 0.81 | HCRTR2 (0.66) | HCRTR2HCRTR1CYP3A4HTR2A | |
| SCHEMBL3486353 | 0.81 | HCRTR2 (0.83) | HCRTR2HCRTR1CYP3A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-02-11 | — | — | US | claimed |
| US-8349872-B2 | Tripyridyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349872-B2 | Tripyridyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-02-11 | — | — | US | disclosed |
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885HCRTR1 2/4885CYP3A4 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.